These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 1763504)

  • 1. The influence of cryopreservation on activity and surface markers of lymphokine-activated killer cells.
    Letellier C; Rameliarison L; Fizet D; Ferrer AM; Vezon G
    Vox Sang; 1991; 61(2):90-5. PubMed ID: 1763504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential effect of cryopreservation on natural killer cell and lymphokine-activated killer cell activities.
    Martí F; Miralles A; Peiró M; Amill B; de Dalmases C; Piñol G; Rueda F; García J
    Transfusion; 1993 Aug; 33(8):651-5. PubMed ID: 8342231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a novel CD56- lymphokine-activated killer cell precursor in cancer patients receiving recombinant interleukin 2.
    McKenzie RS; Simms PE; Helfrich BA; Fisher RI; Ellis TM
    Cancer Res; 1992 Nov; 52(22):6318-22. PubMed ID: 1384959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural killer and lymphokine-activated killer cell activities from human marrow precursors. II. The effects of IL-3 and IL-4.
    Keever CA; Pekle K; Gazzola MV; Collins NH; Bourhis JH; Gillio A
    J Immunol; 1989 Nov; 143(10):3241-9. PubMed ID: 2809200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The presence and cytotoxicity of CD16+ CD2- subset from PBL and NK cells in long-term IL-2 cultures enhanced by Prothymosin-alpha.
    Cordero OJ; Sarandeses C; López-Rodríguez JL; Nogueira M
    Immunopharmacology; 1995 Apr; 29(3):215-23. PubMed ID: 7542644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NK and LAK activities from human marrow progenitors. I. The effects of interleukin-2 and interleukin-1.
    Keever CA; Pekle K; Gazzola MV; Collins NH; Gillio A
    Cell Immunol; 1990 Mar; 126(1):211-26. PubMed ID: 1689220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of lymphokine-activated killer and natural killer cell activities from cryopreserved lymphocytes.
    Kawai H; Komiyama A; Katoh M; Yabuhara A; Miyagawa Y; Akabane T
    Transfusion; 1988; 28(6):531-5. PubMed ID: 3264091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of lymphokine-activated killer cells with low-dose interleukin 2 and interferon-gamma in oral cancer patients.
    Yoneda K; Yamamoto T; Ueta E; Osaki T
    J Clin Immunol; 1992 Jul; 12(4):289-99. PubMed ID: 1512302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pilot study of intralymphatic interleukin-2. I. Cytotoxic and surface marker changes of peripheral blood lymphocytes.
    Shau H; Isacescu V; Ibayashi Y; Tokuda Y; Golub SH; Fahey JL; Sarna GP
    J Biol Response Mod; 1990 Feb; 9(1):71-80. PubMed ID: 2319261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Swainsonine, a glycosylation inhibitor, enhances both lymphocyte efficacy and tumour susceptibility in LAK and NK cytotoxicity.
    Galustian C; Foulds S; Dye JF; Guillou PJ
    Immunopharmacology; 1994; 27(2):165-72. PubMed ID: 7516929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term cultures of human peripheral blood lymphocytes with recombinant human interleukin-2 generate a population of virtually pure CD3+ CD16- CD56- large granular lymphocyte LAK cells.
    Roussel E; Gerrard JM; Greenberg AH
    Clin Exp Immunol; 1990 Nov; 82(2):416-21. PubMed ID: 1700746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin-2 induction of lymphokine-activated killer (LAK) activity in the peripheral blood and bone marrow of acute leukemia patients: II. Feasibility of LAK generation in children with active disease and in remission.
    Adler A; Albo V; Blatt J; Whiteside TL; Herberman RB
    Blood; 1989 Oct; 74(5):1690-7. PubMed ID: 2790193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of recombinant interferon-gamma and interleukin-2 on the generation of lymphokine-activated killer cells in vitro.
    Findley HW; Nasr S; Afify Z; Hnath R; Waldrep K; Ragab AH
    Cancer Invest; 1990; 8(5):493-500. PubMed ID: 2124946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lymphokine-activated killer cell activity after cryopreservation.
    Schmidt-Wolf IG; Aihara M; Negrin RS; Blume KG; Chao NJ
    J Immunol Methods; 1989 Dec; 125(1-2):185-9. PubMed ID: 2607152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generation of human lymphokine-activated killer cells following an IL-2 pulse in elderly cancer patients.
    Provinciali M; Di Stefano G; Stronati S; Fabris N
    Cytokine; 1998 Feb; 10(2):132-9. PubMed ID: 9512903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IL-6 enhances the cytotoxic activity of thymocyte-derived CD56+ cells.
    Iho S; Shau H; Golub SH
    Cell Immunol; 1992 Oct; 144(1):1-10. PubMed ID: 1382861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IL-4 regulation of murine lymphokine-activated killer activity in vitro. Effects on the IL-2-induced expansion, cytotoxicity, and phenotype of lymphokine-activated killer effectors.
    Mulé JJ; Krosnick JA; Rosenberg SA
    J Immunol; 1989 Jan; 142(2):726-33. PubMed ID: 2783444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human lymphokine-activated killer cells are cytotoxic against cells infected with Toxoplasma gondii.
    Subauste CS; Dawson L; Remington JS
    J Exp Med; 1992 Dec; 176(6):1511-9. PubMed ID: 1460415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of human NK cell and LAK cell cytotoxicity and differentiation by PGE2.
    Leung KH
    Cell Immunol; 1989 Oct; 123(2):384-95. PubMed ID: 2507171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lymphokine-activated killer cytotoxicity and lymphocyte subpopulations in patients with acute leukemia.
    Parrado A; Casares S; Rodríguez-Fernández JM
    Leuk Res; 1994 Nov; 18(11):815-22. PubMed ID: 7526078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.